Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026
Medical weight loss at Rock Creek Wellness is physician-led care with GLP-1 medicines, most often tirzepatide, built around what your body is made of, not only what the scale says. Before you start, we run a full set of lab tests and a DEXA body composition scan. Then we measure again as you go, so you can see that the weight you’re losing is fat and that you’re keeping your muscle.
Your care is led by Dr. Angela Barnett, a board-certified family physician who practices integrative and functional medicine, at our clinic in Leawood, serving the Kansas City area.
At a glance
- Who it’s for
- Adults who want medical help to lose weight, with a GLP-1 medicine if it suits them.
- How it starts
- A free consultation, lab tests, then a first visit with a DEXA body composition scan.
- Your medicine
- A compounded or FDA-approved GLP-1 medicine, prescribed for you and shipped to your home.
- Follow-up
- Visits in person or by video, with a DEXA scan usually about every three months.
- Who you’ll see
- Dr. Angela Barnett, a board-certified family physician.
How GLP-1 medicines work
GLP-1 is a hormone your gut releases when you eat. It signals fullness to your brain, slows how quickly your stomach empties and helps your body release insulin after a meal. GLP-1 medicines act like this hormone, so most people feel full sooner and eat less. Tirzepatide also acts on a second gut hormone, GIP.
These medicines are taken alongside changes in eating and activity, not instead of them. In the trials described below, everyone also had diet and exercise advice.
Who medical weight loss is for
Medical weight loss suits adults who carry more body fat than is healthy for them and want medical help to lose it, often after diet and exercise alone haven’t been enough.
- The trials behind these medicines enrolled adults with a body mass index (BMI) of 30 or more, or 27 or more with a weight-related condition such as high blood pressure, high cholesterol or sleep apnea.
- BMI isn’t the whole story. It can’t tell fat from muscle. In 2025 an international commission of obesity experts recommended confirming excess body fat with a direct measure, such as a DEXA scan, rather than relying on BMI alone. Your doctor decides with you, from your body composition, labs, health conditions and history.
- Who it isn’t for. We don’t start GLP-1 medicines for anyone under 18; anyone who is pregnant, breastfeeding or planning a pregnancy soon; or anyone with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2). Your doctor also reviews other conditions, such as past pancreatitis or gallbladder disease, before you start.
How medical weight loss works at Rock Creek Wellness
- Free consultation. Talk with us about your goals and whether medical weight loss suits you.
- Lab tests. Before your first visit, you have blood drawn at a Quest Diagnostics lab, so your results are ready when you meet Dr. Barnett.
- Your first visit, at our Leawood clinic. Dr. Barnett goes through your lab results and reviews your health history, medicines, eating, activity, sleep and goals, and we do your DEXA body composition scan.
- Your plan. From those results, Dr. Barnett prescribes your medicine, if it suits you, and gives you nutrition and exercise guidance, with a focus on protein and strength training to protect your muscle.
- Starting low. You start on a low dose that’s raised step by step, which helps limit side effects. Your medicine is shipped to your home, usually arriving the day after it’s prescribed.
- Follow-up visits. You’re seen in person or by video, as often as your care needs. Video visits are available while you’re in Kansas or Missouri, where Dr. Barnett is licensed. Between visits, you can reach us the same way as for any of your care.
- Measuring as you go. We repeat your DEXA scan during your care, usually about every three months, and use it to adjust your nutrition, training and medicine.
- The long term. Once you reach your goal, you either continue on a maintenance dose or taper the medicine off gradually, decided with you.
What your first lab tests check
Weight gain often has more than one cause. Thyroid problems, insulin resistance, the hormone changes of menopause, low testosterone and some medicines can all contribute, and finding them changes the plan. Your first lab tests, drawn at Quest before your first visit, include:
- Overall health and safety: a complete blood count and a comprehensive metabolic panel, which covers kidney and liver function, electrolytes and blood sugar.
- Blood sugar and insulin: hemoglobin A1c and insulin.
- Thyroid: TSH, free T3 and free T4.
- Hormones: for women, FSH, estradiol, progesterone and testosterone; for men, estradiol and total and free testosterone; for everyone, cortisol.
- Inflammation and nutrients: high-sensitivity C-reactive protein (hs-CRP), vitamin B12 and vitamin D.
Our page on comprehensive blood testing explains our wider testing.
The medicines we prescribe
Dr. Barnett chooses your medicine, where it comes from and your dose from what you need: it may be an FDA-approved brand or a compounded medicine. We prescribe tirzepatide most often.
Compounded GLP-1 medicines. Many of our patients use a compounded medicine, such as compounded tirzepatide. A compounded medicine is prepared for you, from your prescription, by a licensed compounding pharmacy (a 503A pharmacy) and shipped to your home. Compounded medicines aren’t FDA-approved: the FDA doesn’t review them for safety, effectiveness or quality before they’re sold, and the trial results on this page come from the FDA-approved medicines. Ask us which medicine you’d receive, which pharmacy prepares it, and why.
FDA-approved medicines. We also prescribe:
- Wegovy (semaglutide), a weekly injection or a daily tablet. Wegovy is also approved to lower the risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight.
- Zepbound (tirzepatide), a weekly injection. Zepbound is also approved to treat moderate to severe obstructive sleep apnea in adults with obesity.
- Foundayo (orforglipron), a daily tablet approved by the FDA in April 2026.
We don’t bill insurance or handle insurance approvals for medicines. If you’d like a brand medicine, you buy it through a pharmacy or the maker’s self-pay program.
What the trials found. In large randomized trials, alongside diet and activity advice:
- Tirzepatide at its highest dose, 15 mg weekly: people lost an average of 20.9% of their body weight over 72 weeks, against 3.1% on placebo. The trial was funded by Eli Lilly, which makes Zepbound.
- Semaglutide 2.4 mg weekly: an average of 14.9% over 68 weeks, against 2.4% on placebo, and 86% lost at least 5%. The trial was funded by Novo Nordisk, which makes Wegovy.
- The two compared head to head: people on tirzepatide lost an average of 20.2% over 72 weeks, against 13.7% on semaglutide. Everyone knew which medicine they were taking, and the trial was funded by Eli Lilly.
These are averages: some people lose more and some less.
Wegovy is a trademark of Novo Nordisk A/S. Zepbound and Foundayo are trademarks of Eli Lilly and Company.
Protecting muscle and bone
Not all the weight you lose is fat. In body composition studies within the trials, about a quarter of the weight lost on tirzepatide was lean mass, which includes muscle as well as organs and water. On semaglutide, lean mass fell by about 10%, even as the share of the body that is lean went up. A scale can’t tell you which you lost. A DEXA scan can.
That’s why a DEXA scan is part of your care from the start, and why we repeat it, usually about every three months: it shows how much fat and how much lean mass you’re losing, so we can adjust your plan.
Expert groups agree on the basics. A 2025 joint advisory from four obesity and nutrition societies recommends checking body composition and strength before you start, strength training at least three times a week, and often 1.2 to 1.6 grams of protein per kilogram of body weight a day while you’re losing weight. It notes that more protein alone probably isn’t enough without strength training.
Side effects and safety
The most common side effects are nausea, diarrhea, vomiting and constipation. They’re usually mild to moderate and happen mostly while the dose is being raised, which is why we start low and go up gradually. In the trials, about 4 to 7 in 100 people stopped their medicine because of side effects, compared with about 3 in 100 on placebo.
- Gallbladder and pancreas. Gallstones are somewhat more common (in Wegovy’s trials, 1.6% of people against 0.7% on placebo), and pancreatitis is rare. Call us if you have severe stomach pain that doesn’t go away.
- Thyroid. These medicines caused thyroid C-cell tumors in rodents. It isn’t known whether they do in people, which is why they aren’t used by anyone with a personal or family history of medullary thyroid cancer or MEN 2.
- Pregnancy and birth control. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tirzepatide can make birth-control pills less reliable for 4 weeks after you start and after each dose increase, so use a backup method then.
- Surgery. Tell your surgeon or anesthesiologist that you take one. Under 2024 guidance from five medical societies, most people can keep taking it before elective surgery.
- Measuring doses. The FDA has had reports of dosing errors with compounded GLP-1 medicines drawn up from vials. If yours comes in a vial, ask us to go through measuring your dose with you.
Each medicine’s prescribing information lists all of its warnings; links are in the sources below.
When you stop
GLP-1 medicines work while you take them. In the year after people stopped semaglutide in the STEP 1 trial, they regained about two-thirds of the weight they had lost, and improvements such as lower blood pressure and blood sugar drifted back toward where they started. That was an exploratory follow-up of 327 people, funded by Novo Nordisk. Two trials that switched some people to placebo found the same pattern.
So we plan for the long term from the start: building the eating habits and the muscle that help you keep weight off, then either a maintenance dose or tapering off gradually, decided with you.
How our program differs from online GLP-1 programs
Online GLP-1 programs vary. Some include video visits with a clinician. Others work mainly from an online form: you answer questions, a clinician you may never meet or speak with reviews your answers, and the medicine is shipped to you.
The standard of care is the same either way. The Federation of State Medical Boards’ model policy says care by telemedicine “must meet the same standard of care” as care in person, and that prescribing based solely on static online questionnaires is “not acceptable.” Under the Kansas Pharmacy Act, a prescription “issued solely on the basis of an internet-based questionnaire or consultation without an appropriate prescriber-patient relationship is not a valid prescription order.”
These questions are worth asking any program. Here are our answers:
- Who is my doctor, and will I see them in person? Dr. Barnett leads your care. Your first visit is at our Leawood clinic, and follow-ups are in person or by video.
- What do you test and measure? Lab tests before your first visit, then a DEXA body composition scan at that visit and usually about every three months. Every DEXA scan is included in your fees.
- Which medicine will I get, and what will it cost at my dose? An FDA-approved brand or a compounded medicine, chosen for you. We tell you its price before you start and whenever your dose changes.
- What if my lab tests show another problem? If they point to a thyroid or hormone problem, we can treat it here too.
- How do I cancel? There’s no minimum term. You can cancel with written notice at least 7 days before your next billing date.
Cost
Medical weight loss is cash-pay; we don’t bill insurance. You can pay with an HSA or FSA card, and your plan decides which charges qualify, so check with your plan administrator. Your first consultation is free.
- To establish care: $250, which covers your first visit with Dr. Barnett and your DEXA body composition scan. Labs are separate: through your insurance at Quest, or our discounted cash price of $225.
- Each month: $97 a month, which covers your follow-up visits in person or by video, nutrition and exercise guidance, help between visits, and every DEXA scan during your care. It’s billed monthly, with no minimum term, and you can cancel with written notice at least 7 days before your next billing date.
- Your medicine: a separate cost, because it depends on the medicine and dose your doctor prescribes. We bill you for it, and we tell you the price before you start and whenever your dose changes.
- Premier Care members: medical weight loss care is included in Premier Care, our most comprehensive program; the medicine is a separate cost.
You can ask us for a written Good Faith Estimate of your costs before you start.
Weight and hormones
Weight and hormones are often linked. Menopause changes where the body stores fat, and in men, low testosterone often comes with more body fat and less muscle. If your labs point to a hormone problem, we can treat it alongside your weight care; read more about hormone replacement therapy.
Common questions
Can you take over a GLP-1 medicine I started somewhere else?
Yes. Bring your current medicine, dose and any recent lab results to your first visit. We’ll do our own labs and DEXA scan and carry on from there.
Are compounded GLP-1 medicines the same as Wegovy or Zepbound?
No. A compounded medicine is prepared by a pharmacy for one patient from a prescription, and it isn’t FDA-approved, so the FDA hasn’t reviewed its safety, effectiveness or quality. Wegovy, Zepbound and Foundayo are FDA-approved. We prescribe both kinds; ask us about the differences that matter for you.
Do you take insurance?
No. We’re a cash-pay clinic, and we don’t bill insurance or handle insurance approvals for medicines.
Pills or injections?
Both exist. Wegovy comes as a weekly injection or a daily tablet, Foundayo is a daily tablet, and Zepbound is a weekly injection. Your doctor will go through what suits you.
How soon will I see results?
Gradually. You start on a low dose that’s raised step by step, and the trial results above were measured after 68 to 72 weeks of treatment.
Will I lose muscle?
Some of the weight anyone loses is lean mass. We measure it with DEXA scans during your care, and your plan includes protein and strength training to help protect your muscle.
Can I have video visits?
Yes, for follow-ups, while you’re in Kansas or Missouri, where Dr. Barnett is licensed. Your first visit is at our Leawood clinic, because it includes your DEXA scan.
Sources
Show all 18 sourcesHide sources
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 2021.
- Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine, 2022.
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022.
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 2021.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 2024.
- Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 2025.
- Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Society, 2021.
- Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. The American Journal of Clinical Nutrition, 2025.
- Definition and diagnostic criteria of clinical obesity. The Lancet Diabetes & Endocrinology, 2025.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine, 2023.
- Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surgery for Obesity and Related Diseases, 2024.
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration, 2026.
- FDA Approves First New Molecular Entity Under National Priority Voucher Program. U.S. Food and Drug Administration, 2026.
- WEGOVY (semaglutide) injection; WEGOVY (semaglutide) tablet: prescribing information. DailyMed (U.S. National Library of Medicine), 2026.
- ZEPBOUND (tirzepatide) injection: prescribing information. DailyMed (U.S. National Library of Medicine), 2026.
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. The New England Journal of Medicine, 2025.
- The Appropriate Use of Telemedicine Technologies in the Practice of Medicine. Federation of State Medical Boards, 2022.
- K.S.A. 65-1626, Kansas Pharmacy Act definitions. Kansas Office of Revisor of Statutes.
